{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:20Z","timestamp":1786980560086,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We aimed to identify the most cost-effective of all prophylactic measures available in Switzerland for women not yet affected by breast and ovarian cancer who tested positive for a\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prophylactic bilateral mastectomy (PBM), salpingo-oophorectomy (PBSO), combined PBM&amp;PBSO and chemoprevention (CP) initiated at age 40\u00a0years were compared with intensified surveillance (IS). A Markov model with a life-long time horizon was developed from the perspective of the Swiss healthcare system using mainly literature-derived data to evaluate costs, quality-adjusted life years (QALYs) and survival. Costs and QALYs were discounted by 3% per year. Robustness of the results was tested with deterministic and probabilistic sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All prophylactic measures were found to be cost-saving with an increase in QALYs and life years (LYs) compared to IS. PBM&amp;PBSO were found to be most cost-effective and dominated all other strategies in women with a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      or\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation. Lifetime costs averaged to 141,293 EUR and 14.5 QALYs per woman with a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      mutation under IS, versus 76,639 EUR and 19.2 QALYs for PBM&amp;PBSO. Corresponding results for IS per woman with a\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation were 102,245 EUR and 15.5 QALYs, versus 60,770 EUR and 19.9 QALYs for PBM&amp;PBSO. The results were found to be robust in sensitivity analysis; no change in the dominant strategy for either\n                      <jats:italic>BRCA<\/jats:italic>\n                      -mutation was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      All more invasive strategies were found to increase life expectancy and quality of life of women with a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      or\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation and were cost-saving for the Swiss healthcare system compared to IS.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-021-01396-9","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T06:02:50Z","timestamp":1636696970000},"page":"807-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost\u2013utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-6821","authenticated-orcid":false,"given":"Claudine","family":"Bommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Lupatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"B\u00fcrki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwenkglenks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"issue":"4","key":"1396_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice, C., et al.: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4), 524\u2013548 (2017)","journal-title":"JAMA Oncol"},{"issue":"12","key":"1396_CR2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","volume":"14","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez, R., et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12), 1165\u20131174 (2013)","journal-title":"Lancet Oncol"},{"issue":"23","key":"1396_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K.B., et al.: Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23), 2402\u20132416 (2017)","journal-title":"JAMA"},{"issue":"35","key":"1396_CR4","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser, M.K., et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35), 5887\u20135892 (2009)","journal-title":"J Clin Oncol"},{"issue":"44","key":"1396_CR5","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh, T., et al.: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108(44), 18032\u201318037 (2011)","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1396_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DD Bowtell","year":"2010","unstructured":"Bowtell, D.D.: The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11), 803\u2013808 (2010)","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1396_CR7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois, A., et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115(6), 1234\u20131244 (2009)","journal-title":"Cancer"},{"issue":"5","key":"1396_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou, A., et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5), 1117\u20131130 (2003)","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1396_CR9","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1186\/s13058-014-0474-y","volume":"16","author":"AB Spurdle","year":"2014","unstructured":"Spurdle, A.B., et al.: Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 16(6), 3419 (2014)","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1396_CR10","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1186\/s13058-014-0492-9","volume":"16","author":"KB Kuchenbaecker","year":"2014","unstructured":"Kuchenbaecker, K.B., et al.: Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 16(6), 3416 (2014)","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1396_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1503523","volume":"374","author":"LC Hartmann","year":"2016","unstructured":"Hartmann, L.C., Lindor, N.M.: The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374(5), 454\u2013468 (2016)","journal-title":"N Engl J Med"},{"key":"1396_CR12","first-page":"CD012464","volume":"8","author":"GU Eleje","year":"2018","unstructured":"Eleje, G.U., et al.: Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev 8, CD012464 (2018)","journal-title":"Cochrane Database Syst Rev"},{"key":"1396_CR13","first-page":"CD002748","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine, N.E., et al.: Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 4, CD002748 (2018)","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"1396_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","volume":"35","author":"AN Rosenthal","year":"2017","unstructured":"Rosenthal, A.N., et al.: Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol 35(13), 1411\u20131420 (2017)","journal-title":"J Clin Oncol"},{"issue":"22","key":"1396_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys, S.S., et al.: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22), 2295\u20132303 (2011)","journal-title":"JAMA"},{"issue":"14","key":"1396_CR16","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","volume":"23","author":"SJ Skates","year":"2017","unstructured":"Skates, S.J., et al.: Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk\u2014combined results from two screening trials. Clin Cancer Res 23(14), 3628\u20133637 (2017)","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1396_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher, B., et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18), 1371\u20131388 (1998)","journal-title":"J Natl Cancer Inst"},{"issue":"9922","key":"1396_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick, J., et al.: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922), 1041\u20131048 (2014)","journal-title":"Lancet"},{"issue":"3","key":"1396_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann, V.R., et al.: Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res Treat 125(3), 837\u2013847 (2011)","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1396_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10198-017-0887-5","volume":"19","author":"D Muller","year":"2018","unstructured":"Muller, D., et al.: Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ 19(3), 341\u2013353 (2018)","journal-title":"Eur J Health Econ"},{"key":"1396_CR21","unstructured":"Network, N.C.C.: Breast Cancer Risk Reduction. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_risk.pdf (2021)"},{"key":"1396_CR22","unstructured":"Bundesamt f\u00fcr Gesundheit (BAG)\u2014Direktionsbereich Kranken- und Unfallversicherung; Referenzdokument \"\u00dcberwachungsprotokoll\" zu Artikel 12d Absatz 1 Buchstabe d der Krankenpflege-Leistungsverordnung (KLV) in Anlehnung an NICE Clinical Guideline 164 vom Juni 2013 (Stand 02\/2015)."},{"issue":"11","key":"1396_CR23","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jtho.2016.05.032","volume":"11","author":"K Matter-Walstra","year":"2016","unstructured":"Matter-Walstra, K., et al.: A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol 11(11), 1846\u20131855 (2016)","journal-title":"J Thorac Oncol"},{"key":"1396_CR24","unstructured":"Bundesgericht.: Auszug aus dem Urteil der II. sozialrechtlichen Abteilung i.S. Publisana Krankenversicherung gegen F. (Beschwerde in \u00f6ffentlich-rechtlichen Angelegenheiten) 9C_334\/2010 vom 23. November 2010. http:\/\/relevancy.bger.ch\/php\/clir\/http\/index.php?highlight_docid=atf%3A%2F%2F136-V-395%3Ade&lang=de&type=show_document (2010)"},{"issue":"7","key":"1396_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cncr.27842","volume":"119","author":"SM Domchek","year":"2013","unstructured":"Domchek, S.M., et al.: Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 119(7), 1344\u20131348 (2013)","journal-title":"Cancer"},{"issue":"2","key":"1396_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1245\/s10434-014-3883-3","volume":"22","author":"K Yao","year":"2015","unstructured":"Yao, K., et al.: Nipple-sparing mastectomy in BRCA1\/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol 22(2), 370\u2013376 (2015)","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1396_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","volume":"113","author":"WH Parker","year":"2009","unstructured":"Parker, W.H., et al.: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses\u2019 health study. Obstet Gynecol 113(5), 1027\u20131037 (2009)","journal-title":"Obstet Gynecol"},{"issue":"8","key":"1396_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/archinternmed.2011.121","volume":"171","author":"VL Jacoby","year":"2011","unstructured":"Jacoby, V.L., et al.: Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women\u2019s Health Initiative Observational Study. Arch Intern Med 171(8), 760\u2013768 (2011)","journal-title":"Arch Intern Med"},{"issue":"11","key":"1396_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","volume":"91","author":"WA Rocca","year":"2016","unstructured":"Rocca, W.A., et al.: Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc 91(11), 1577\u20131589 (2016)","journal-title":"Mayo Clin Proc"},{"key":"1396_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2016.07.014","volume":"66","author":"M Klar","year":"2016","unstructured":"Klar, M., et al.: Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group GINECO and NSGO. Eur J Cancer 66, 114\u2013124 (2016)","journal-title":"Eur J Cancer"},{"issue":"1","key":"1396_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","volume":"130","author":"LM Landrum","year":"2013","unstructured":"Landrum, L.M., et al.: Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study. Gynecol Oncol 130(1), 12\u201318 (2013)","journal-title":"Gynecol Oncol"},{"key":"1396_CR32","doi-asserted-by":"crossref","unstructured":"Chirlaque, M.D., et al.: Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study. pp. S107\u2013S113 (2017)","DOI":"10.1097\/CEJ.0000000000000302"},{"key":"1396_CR33","unstructured":"Swiss Federal Office of Statistics\u2014mortality rates. http:\/\/www.bfs.admin.ch"},{"key":"1396_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv217","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen, B.A., et al.: Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst (2015). https:\/\/doi.org\/10.1093\/jnci\/djv217","journal-title":"J Natl Cancer Inst"},{"key":"1396_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx038","author":"J Kotsopoulos","year":"2017","unstructured":"Kotsopoulos, J., et al.: Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2017). https:\/\/doi.org\/10.1093\/jnci\/djx038","journal-title":"J Natl Cancer Inst"},{"issue":"9354","key":"1396_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick, J., et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354), 296\u2013300 (2003)","journal-title":"Lancet"},{"issue":"9880","key":"1396_CR37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick, J., et al.: Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880), 1827\u20131834 (2013)","journal-title":"Lancet"},{"issue":"3","key":"1396_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/0008-5472.CAN-03-2970","volume":"64","author":"WD Foulkes","year":"2004","unstructured":"Foulkes, W.D., et al.: The prognostic implication of the basal-like (cyclin E high\/p27 low\/p53+\/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64(3), 830\u2013835 (2004)","journal-title":"Cancer Res"},{"issue":"25","key":"1396_CR39","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips, K.A., et al.: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31(25), 3091\u20133099 (2013)","journal-title":"J Clin Oncol"},{"issue":"4","key":"1396_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djk050","volume":"99","author":"TJ Powles","year":"2007","unstructured":"Powles, T.J., et al.: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4), 283\u2013290 (2007)","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1396_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance, G.W.: Measurement of health state utilities for economic appraisal. J Health Econ 5(1), 1\u201330 (1986)","journal-title":"J Health Econ"},{"issue":"4","key":"1396_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan, P.W., Ghushchyan, V.: Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 26(4), 410\u2013420 (2006)","journal-title":"Med Decis Making"},{"issue":"5","key":"1396_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/erp.10.65","volume":"10","author":"T Peasgood","year":"2010","unstructured":"Peasgood, T., Ward, S.E., Brazier, J.: Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res 10(5), 553\u2013566 (2010)","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"1396_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jval.2012.05.003","volume":"15","author":"R Ara","year":"2012","unstructured":"Ara, R., Wailoo, A.: Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health 15(6), 971\u2013974 (2012)","journal-title":"Value Health"},{"issue":"4","key":"1396_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/micr.10138","volume":"23","author":"A Thoma","year":"2003","unstructured":"Thoma, A., et al.: Cost-utility analysis comparing free and pedicled TRAM flap for breast reconstruction. Microsurgery 23(4), 287\u2013295 (2003)","journal-title":"Microsurgery"},{"issue":"3","key":"1396_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ygyno.2017.03.025","volume":"145","author":"LJ Havrilesky","year":"2017","unstructured":"Havrilesky, L.J., et al.: Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous\/serous-like uterine cancers in BRCA1 mutation carriers. Gynecol Oncol 145(3), 549\u2013554 (2017)","journal-title":"Gynecol Oncol"},{"issue":"22","key":"1396_CR47","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2011.35.6956","volume":"29","author":"B Zendejas","year":"2011","unstructured":"Zendejas, B., et al.: Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol 29(22), 2993\u20133000 (2011)","journal-title":"J Clin Oncol"},{"issue":"7278","key":"1396_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/bmj.322.7278.76","volume":"322","author":"MB Hatcher","year":"2001","unstructured":"Hatcher, M.B., Fallowfield, L., A\u2019Hern, R.: The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ 322(7278), 76 (2001)","journal-title":"BMJ"},{"key":"1396_CR49","unstructured":"Swiss DRG catalogue. https:\/\/www.swissdrg.org\/de"},{"key":"1396_CR50","unstructured":"Swiss Tarmed catalogue. https:\/\/www.tarmed-browser.ch\/de\/leistungen"},{"key":"1396_CR51","unstructured":"Bundesamt f\u00fcr Gesundheit (BAG)\u2014Swiss medication list (Spezialit\u00e4tenliste; SL). http:\/\/www.xn--spezialittenliste-yqb.ch\/"},{"issue":"4","key":"1396_CR52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer, P., et al.: AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics 34(4), 349\u2013361 (2016)","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1396_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","volume":"144","author":"K Anderson","year":"2006","unstructured":"Anderson, K., et al.: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6), 397\u2013406 (2006)","journal-title":"Ann Intern Med"},{"issue":"3","key":"1396_CR54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.1998.16.3.979","volume":"16","author":"VR Grann","year":"1998","unstructured":"Grann, V.R., et al.: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16(3), 979\u2013985 (1998)","journal-title":"J Clin Oncol"},{"issue":"7","key":"1396_CR55","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejca.2008.02.025","volume":"44","author":"J Norum","year":"2008","unstructured":"Norum, J., et al.: Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer 44(7), 963\u2013971 (2008)","journal-title":"Eur J Cancer"},{"key":"1396_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.breast.2017.02.008","volume":"32","author":"MG Schrauder","year":"2017","unstructured":"Schrauder, M.G., et al.: Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast 32, 186\u2013191 (2017)","journal-title":"Breast"},{"issue":"10","key":"1396_CR57","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jama.2018.1150","volume":"319","author":"I Papanicolas","year":"2018","unstructured":"Papanicolas, I., Woskie, L.R., Jha, A.K.: Health care spending in the United States and other high-income countries. JAMA 319(10), 1024\u20131039 (2018)","journal-title":"JAMA"},{"key":"1396_CR58","unstructured":"Wieser S., T.T., Riguzzi M., Fischer B., Telser H., Pletscher M., Eichler K., Trost M., Schwenkglenks M.: Die Kosten der nicht\u00fcbertragbaren Krankheiten in der Schweiz\u2014Schlussbericht (2014)"},{"issue":"9","key":"1396_CR59","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe, K.A., et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9), 2017\u20132022 (2008)","journal-title":"Int J Cancer"},{"issue":"9","key":"1396_CR60","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.2196\/resprot.8138","volume":"6","author":"MC Katapodi","year":"2017","unstructured":"Katapodi, M.C., et al.: Cancer predisposition cascade screening for hereditary breast\/ovarian cancer and lynch syndromes in Switzerland: study protocol. JMIR Res Protoc 6(9), e184 (2017)","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"1396_CR61","doi-asserted-by":"publisher","first-page":"e1361","DOI":"10.1016\/j.clbc.2018.07.015","volume":"18","author":"M D'Alonzo","year":"2018","unstructured":"D\u2019Alonzo, M., et al.: Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers. Clin Breast Cancer 18(6), e1361\u2013e1366 (2018)","journal-title":"Clin Breast Cancer"},{"issue":"28","key":"1396_CR62","doi-asserted-by":"publisher","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","volume":"23","author":"JB Madalinska","year":"2005","unstructured":"Madalinska, J.B., et al.: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28), 6890\u20136898 (2005)","journal-title":"J Clin Oncol"},{"issue":"3","key":"1396_CR63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","volume":"1","author":"K Metcalfe","year":"2015","unstructured":"Metcalfe, K., et al.: Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 1(3), 306\u2013313 (2015)","journal-title":"JAMA Oncol"},{"issue":"6","key":"1396_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ijc.10641","volume":"101","author":"P Moller","year":"2002","unstructured":"Moller, P., et al.: Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101(6), 555\u2013559 (2002)","journal-title":"Int J Cancer"},{"issue":"2","key":"1396_CR65","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10549-016-3749-4","volume":"156","author":"T Huzarski","year":"2016","unstructured":"Huzarski, T., et al.: The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 156(2), 371\u2013378 (2016)","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1396_CR66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.maturitas.2010.03.018","volume":"66","author":"MJ Kenkhuis","year":"2010","unstructured":"Kenkhuis, M.J., et al.: Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers. Maturitas 66(3), 310\u2013314 (2010)","journal-title":"Maturitas"},{"issue":"1","key":"1396_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ygyno.2018.10.040","volume":"152","author":"E Hall","year":"2019","unstructured":"Hall, E., et al.: Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 152(1), 145\u2013150 (2019)","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1396_CR68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2015.11.002","volume":"140","author":"PE Tucker","year":"2016","unstructured":"Tucker, P.E., et al.: Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 140(1), 95\u2013100 (2016)","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1396_CR69","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/pon.2041","volume":"22","author":"A Finch","year":"2013","unstructured":"Finch, A., et al.: The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 22(1), 212\u2013219 (2013)","journal-title":"Psychooncology"},{"issue":"1","key":"1396_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cge.12233","volume":"85","author":"KA Metcalfe","year":"2014","unstructured":"Metcalfe, K.A., et al.: Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. Clin Genet 85(1), 21\u201330 (2014)","journal-title":"Clin Genet"},{"issue":"3","key":"1396_CR71","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamasurg.2016.4749","volume":"152","author":"R Jagsi","year":"2017","unstructured":"Jagsi, R., et al.: Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg 152(3), 274\u2013282 (2017)","journal-title":"JAMA Surg"},{"issue":"6","key":"1396_CR72","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.breast.2010.05.003","volume":"19","author":"J Gahm","year":"2010","unstructured":"Gahm, J., Wickman, M., Brandberg, Y.: Bilateral prophylactic mastectomy in women with inherited risk of breast cancer\u2013prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19(6), 462\u2013469 (2010)","journal-title":"Breast"},{"issue":"24","key":"1396_CR73","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1200\/JCO.2007.13.9568","volume":"26","author":"Y Brandberg","year":"2008","unstructured":"Brandberg, Y., et al.: Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24), 3943\u20133949 (2008)","journal-title":"J Clin Oncol"},{"issue":"12","key":"1396_CR74","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","volume":"14","author":"BA Heemskerk-Gerritsen","year":"2007","unstructured":"Heemskerk-Gerritsen, B.A., et al.: Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14(12), 3335\u20133344 (2007)","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1396_CR75","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/SLA.0b013e318214b55a","volume":"253","author":"B Arver","year":"2011","unstructured":"Arver, B., et al.: Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg 253(6), 1147\u20131154 (2011)","journal-title":"Ann Surg"},{"issue":"1","key":"1396_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/SLA.0000000000002033","volume":"267","author":"EG Wilkins","year":"2018","unstructured":"Wilkins, E.G., et al.: Complications in postmastectomy breast reconstruction: one-year outcomes of the mastectomy reconstruction outcomes consortium (MROC) study. Ann Surg 267(1), 164\u2013170 (2018)","journal-title":"Ann Surg"},{"issue":"9","key":"1396_CR77","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ejca.2011.10.020","volume":"48","author":"M den Heijer","year":"2012","unstructured":"den Heijer, M., et al.: Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur J Cancer 48(9), 1263\u20131268 (2012)","journal-title":"Eur J Cancer"},{"issue":"9","key":"1396_CR78","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1245\/s10434-017-5915-2","volume":"24","author":"CM McCarthy","year":"2017","unstructured":"McCarthy, C.M., et al.: Impact of bilateral prophylactic mastectomy and immediate reconstruction on health-related quality of life in women at high risk for breast carcinoma: results of the mastectomy reconstruction outcomes consortium study. Ann Surg Oncol 24(9), 2502\u20132508 (2017)","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1396_CR79","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/07399332.2016.1267182","volume":"38","author":"M Mahat-Shamir","year":"2017","unstructured":"Mahat-Shamir, M., Possick, C.: The experience of women carriers of BRCA mutations following risk-reducing surgery: a cultural perspective. Health Care Women Int 38(4), 344\u2013360 (2017)","journal-title":"Health Care Women Int"},{"key":"1396_CR80","volume-title":"Famili\u00e4rer Bruskrebs\u2014Diagnose, Beratung, Therapie und Langzeitbetreuung","author":"N B\u00fcrki","year":"2012","unstructured":"B\u00fcrki, N., et al.: Famili\u00e4rer Bruskrebs\u2014Diagnose, Beratung, Therapie und Langzeitbetreuung. Schulthess Verlag, Genf (2012)"},{"issue":"3","key":"1396_CR81","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hec.1486","volume":"19","author":"R Anderson","year":"2010","unstructured":"Anderson, R.: Systematic reviews of economic evaluations: utility or futility? Health Econ 19(3), 350\u2013364 (2010)","journal-title":"Health Econ"},{"issue":"4","key":"1396_CR82","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick, J., et al.: Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4), 272\u2013282 (2007)","journal-title":"J Natl Cancer Inst"},{"issue":"9847","key":"1396_CR83","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(12)60990-8","volume":"380","author":"D Bainbridge","year":"2012","unstructured":"Bainbridge, D., et al.: Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis. Lancet 380(9847), 1075\u20131081 (2012)","journal-title":"Lancet"},{"issue":"1","key":"1396_CR84","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","volume":"16","author":"A Hennigs","year":"2016","unstructured":"Hennigs, A., et al.: Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 16(1), 734 (2016)","journal-title":"BMC Cancer"},{"issue":"40","key":"1396_CR85","doi-asserted-by":"publisher","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta, Z., et al.: Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 95(40), e4975 (2016)","journal-title":"Medicine (Baltimore)"},{"issue":"26","key":"1396_CR86","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K., et al.: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26), 2495\u20132505 (2018)","journal-title":"N Engl J Med"},{"issue":"1","key":"1396_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CEJ.0b013e3283552e28","volume":"22","author":"T Chen","year":"2013","unstructured":"Chen, T., et al.: Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur J Cancer Prev 22(1), 59\u201367 (2013)","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"1396_CR88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-009-0373-6","volume":"119","author":"VR Grann","year":"2010","unstructured":"Grann, V.R., et al.: Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res Treat 119(1), 177\u2013184 (2010)","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1396_CR89","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40001-019-0391-8","volume":"24","author":"MG Schrauder","year":"2019","unstructured":"Schrauder, M.G., et al.: Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. Eur J Med Res 24(1), 32 (2019)","journal-title":"Eur J Med Res"},{"issue":"3","key":"1396_CR90","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/PRS.0000000000002428","volume":"138","author":"NM Krishnan","year":"2016","unstructured":"Krishnan, N.M., et al.: Is single-stage prosthetic reconstruction cost effective? a cost-utility analysis for the use of direct-to-implant breast reconstruction relative to expander-implant reconstruction in postmastectomy patients. Plast Reconstr Surg 138(3), 537\u2013547 (2016)","journal-title":"Plast Reconstr Surg"},{"issue":"35\u201336","key":"1396_CR91","first-page":"593","volume":"112","author":"B Gerber","year":"2015","unstructured":"Gerber, B., et al.: Breast reconstruction following cancer treatment. Dtsch Arztebl Int 112(35\u201336), 593\u2013600 (2015)","journal-title":"Dtsch Arztebl Int"},{"issue":"22","key":"1396_CR92","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/JCO.2016.69.9561","volume":"35","author":"AL Pusic","year":"2017","unstructured":"Pusic, A.L., et al.: Patient-reported outcomes 1 year after immediate breast reconstruction: results of the mastectomy reconstruction outcomes consortium study. J Clin Oncol 35(22), 2499\u20132506 (2017)","journal-title":"J Clin Oncol"},{"issue":"1","key":"1396_CR93","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos, J., et al.: Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 150(1), 85\u201391 (2018)","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1396_CR94","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(12)70042-6","volume":"13","author":"S Litiere","year":"2012","unstructured":"Litiere, S., et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13(4), 412\u2013419 (2012)","journal-title":"Lancet Oncol"},{"issue":"9","key":"1396_CR95","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek, S.M., et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967\u2013975 (2010)","journal-title":"JAMA"},{"issue":"1","key":"1396_CR96","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1083\/jcb.200611141","volume":"177","author":"G Cumming","year":"2007","unstructured":"Cumming, G., Fidler, F., Vaux, D.L.: Error bars in experimental biology. J Cell Biol 177(1), 7\u201311 (2007)","journal-title":"J Cell Biol"},{"issue":"6","key":"1396_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck, T.R., et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6), 1055\u20131062 (2004)","journal-title":"J Clin Oncol"},{"issue":"10","key":"1396_CR98","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","volume":"17","author":"JC Boughey","year":"2010","unstructured":"Boughey, J.C., et al.: Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10), 2702\u20132709 (2010)","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1396_CR99","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","volume":"113","author":"LJ Havrilesky","year":"2009","unstructured":"Havrilesky, L.J., et al.: Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 113(2), 216\u2013220 (2009)","journal-title":"Gynecol Oncol"},{"issue":"11","key":"1396_CR100","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J.A., et al.: Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17(11), 1579\u20131589 (2016)","journal-title":"Lancet Oncol"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-021-01396-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-021-01396-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-021-01396-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T04:08:22Z","timestamp":1654661302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-021-01396-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1007\/s10198-021-01396-9","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"20 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}